The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis

J Neurol Sci. 2024 Apr 15:459:122970. doi: 10.1016/j.jns.2024.122970. Epub 2024 Mar 20.

Abstract

Background: Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions that lead to involuntary postures or repetitive movements. Genetic mutations are being increasingly recognized as a cause of dystonia. Deep brain stimulation (DBS) is one of the limited treatment options available. However, there are varying reports on its efficacy in genetic dystonias. This systematic review of the characteristics of genetic dystonias treated with DBS and their outcomes aims to aid in the evaluation of eligibility for such treatment.

Methods: We performed a PUBMED search of all papers related to genetic dystonias and DBS up until April 2022. In addition to performing a systematic review, we also performed a meta-analysis to assess the role of the mutation on DBS response. We included cases that had a confirmed genetic mutation and DBS along with pre-and post-operative BFMDRS.

Results: Ninety-one reports met our inclusion criteria and from them, 235 cases were analyzed. Based on our analysis DYT-TOR1A dystonia had the best evidence for DBS response and Rapid-Onset Dystonia Parkinsonism was among the least responsive to DBS.

Conclusion: While our report supports the role of genetics in DBS selection and response, it is limited by the rarity of the individual genetic conditions, the reliance on case reports and case series, and the limited ability to obtain genetic testing on a large scale in real-time as opposed to retrospectively as in many cases.

Keywords: Deep brain stimulation; Dystonia; Genetics.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Deep Brain Stimulation*
  • Dystonia* / genetics
  • Dystonia* / therapy
  • Dystonic Disorders* / genetics
  • Dystonic Disorders* / therapy
  • Globus Pallidus
  • Humans
  • Molecular Chaperones
  • Retrospective Studies
  • Treatment Outcome

Substances

  • TOR1A protein, human
  • Molecular Chaperones